BioNotebook: Sparks raises $72.8m; Array/Biogen, Oncothyreon/Celldex collaborate; CIRM grants; BioCryst offering
This article was originally published in Scrip
Executive Summary
Spark Therapeutics has raised its second venture capital round in less than a year with a $72.8m Series B financing, which primarily will pay for development and commercialization of a gene therapy to treat inherited blindness caused by mutations of the RPE65 gene.